...
首页> 外文期刊>American Journal of Cancer Research >Artesunate induces ER-derived-ROS-mediated cell death by disrupting labile iron pool and iron redistribution in hepatocellular carcinoma cells
【24h】

Artesunate induces ER-derived-ROS-mediated cell death by disrupting labile iron pool and iron redistribution in hepatocellular carcinoma cells

机译:青蒿琥酯通过破坏肝细胞癌细胞中的不稳定铁池和铁再分配来诱导ER-rosived-ROS介导的细胞死亡

获取原文
           

摘要

Aberrant iron homeostasis is a typical characteristic of Hepatocellular carcinoma (HCC), and perturbation of iron metabolism is an effective strategy for HCC therapy. However, there are few safe and effective targeting agents available in clinical practices. The artemisinin and its derivatives have shown potential anti-cancer activity by disturbing cellular iron homeostasis, but the specific mechanism is still unclear. In this study, we demonstrate that Artesunate (ART), a water-soluble anti-malaria agent in clinical use, can regulate the labile iron pool (LIP) and effectively induce ROS-dependent cell death in multiple HCC cells. Mechanistically, ART increases the LIP by promoting lysosomal degradation of iron-storage protein ferritin through acidizing lysosomes. Then the accumulation of labile iron in the endoplasmic reticulum (ER) promotes excessive reactive oxygen species (ROS) production and severe ER disruption, which leads to cell death. Our results provide a new understanding of how ART modulates iron metabolism in HCC cells at the subcellular level, demonstrate the significance of endoplasmic reticulum as iron-vulnerability of HCC cells. More importantly, our findings suggest ART is a safe and potential anti-HCC agent via disturbing iron homeostasis.
机译:异常铁稳态是肝细胞癌(HCC)的典型特征,铁代谢的扰动是HCC治疗的有效策略。但是,临床实践中有很少有安全有效的靶向剂。通过扰乱细胞铁稳态,蒿蛋白及其衍生物已经显示出潜在的抗癌活性,但具体机制仍不清楚。在这项研究中,我们证明了临床使用中的水溶性抗疟疾剂,可以调节不稳定的铁池(唇)并有效地在多个HCC细胞中诱导ROS依赖性细胞死亡。机械地,通过促进铁储存蛋白铁蛋白的溶酶体降解通过酸化溶质来增加唇缘。然后在内质网(ER)中的不稳定铁的积累促进过量的活性氧(ROS)产生和严重的ER破坏,这导致细胞死亡。我们的研究结果提供了新的了解艺术如何调节亚细胞水平的HCC细胞中的铁代谢,证明内质网作为HCC细胞的铁脆性的重要性。更重要的是,我们的研究结果表明艺术是通过扰乱铁袜的安全和潜在的抗HCC药剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号